Products | Analytics Software | August 16, 2018

mPower Clinical Analytics

mPower Clinical Analytics

Related Content

Registration is now open for #ASTRO24
News | ASTRO
American Society for Radiation Oncology (ASTRO) to Host Annual Meeting in Washington, DC, Sept. 29-Oct. 2

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
St. Vincent’s Private Hospital, the largest acute private hospital in Dublin, announced a five-year contract with AGFA HealthCare including Enterprise Imaging for both radiology and breast imaging
News | Enterprise Imaging
St. Vincent’s Private Hospital, the Largest Acute Private Hospital in Dublin, Chooses AGFA HealthCare’s Enterprise Imaging for Radiology

May 16, 2024 — AGFA HealthCare announced that St. Vincent’s Private Hospital in Dublin, Ireland, has chosen to implement ...

Time May 16, 2024
arrow
Partnership addresses pressing challenges in the US healthcare system and is set to advance radiology workflow for US healthcare providers
News | Artificial Intelligence
deepc Expands US Presence, Enabling Radiology AI Access for Numerous Healthcare Practices via ImagineSoftware Partnership

May 16, 2024 — deepc, the globally recognized digital medicine pioneer and market leader behind the leading AI operating ...

Time May 16, 2024
arrow
Philips recently partnered with Amazon Web Services (AWS) to develop Philips HealthSuite Imaging
Sponsored Content | Case Study | Enterprise Imaging
Delivering Comprehensive Enterprise Imaging from the Cloud

Having the most efficient clinical workflows with enhanced diagnostic capabilities is a major goal for clinicians and ...

Time May 16, 2024
arrow
Ground-truth manual organ segmentations (yellow) vs. DynUNet-TL (green) and TotalSegmentator (red) predictions
News | Enterprise Imaging
etherFAX Expands its Hyland Partnership by Launching New Cloud Fax Integration

May 15, 2024 — etherFAX announced the expansion of its partnership with Hyland, a leading global provider of intelligent ...

Time May 15, 2024
arrow
News | Cybersecurity
New Data Reveals Healthcare Industry is Facing Rising Cyberattacks

May 13, 2024 — In the wake of the cybersecurity breach targeting the prominent healthcare system Ascension, a new study ...

Time May 13, 2024
arrow
Prospective pilot research study is first of its kind to attempt to quantify the impact of playing, training, and rest over a professional basketball season on musculoskeletal health with a cohort of elite professional basketball players from multiple teams
News | Radiology Imaging
NBA, NBPA, and NGBPU Collaborate with GE HealthCare and MedStar Health on Musculoskeletal and Joint Health Study

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
Acquisition of Mariana Oncology brings together two companies at the forefront of novel radiopharmaceutical development, with a total potential value of up to $1.75 billion
News | Radiation Oncology
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
Justin Hernandez, MD
News | ARRS
Race, Gender and Risk of Not Matching In Diagnostic Radiology

May 8, 2024 — Compared to males, women in radiology are at a consistently higher risk of not matching into diagnostic ...

Time May 08, 2024
arrow
Swedish biotech company Ascelia Pharma has announced its liver imaging drug candidate, Orviglance, significantly improved visualization of focal liver lesions, having successfully met the primary endpoint in the pivotal Phase 3 study, SPARKLE. CEO Magnus Corftizen shown here, offered an update on the first-in-class contrast agent for use in liver MRI in patients with severely impaired kidney function which has been granted FDA Orphan Drug Designation.
News | Contrast Media
Ascelia Pharma Meets Primary Endpoint in Phase 3 Study of Orviglance Liver Imaging Contrast Agent Drug Candidate

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now